You are here

  • Home
  • Archive
  • Volume 32, Issue 9
  • ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Article metrics

Article menu

Download PDFPDF

Clinical trial
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation
Free

 

Online download statistics by month:

Online download statistics by month: April 2022 to April 2024

AbstractFullPdf
Apr 202233763
May 202220162
Jun 2022576165
Jul 202227959
Aug 2022204117
Sep 202228221130
Oct 202226422234
Nov 202216912624
Dec 2022965920
Jan 2023705011
Feb 2023825918
Mar 2023735415
Apr 2023473628
May 2023766130
Jun 20231015514
Jul 2023845724
Aug 20231066636
Sep 2023836730
Oct 2023835822
Nov 2023785837
Dec 2023574613
Jan 2024794419
Feb 2024694624
Mar 2024685663
Apr 2024443719
Total36081512537